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Epithelial ovarian cancer is the most lethal gynaecologic malig-
nancy in Western countries. In about 70% of the patients the
disease presents at an advanced stage meaning that widespread
intraperitoneal metastasis has already occurred. Despite a high
overall clinical response rate to modern treatment, including
debulking surgery and platinum-based chemotherapy, the reported
5-year survival rates for women with advanced ovarian cancer are
still less than 25%. Although the majority of patients initially
respond to chemotherapy, two thirds will die due to progressive
disease that has become refractory to chemotherapy (Ozols et al,
1992). The prognostic characterization of ovarian cancer patients
is currently routinely based on clinico-pathological parameters.
These features, however, have been proven insufficient to define
prognostic subgroups and to accurately predict response to
chemotherapy. Identification of new prognostic factors to select
patients with good or bad outcome might help to improve treat-
ment. 
The cytotoxic effect of cisplatin and its analogues is mediated
through the interaction with DNA and formation of a variety of
DNA adducts, followed by the induction of programmed cell death
(apoptosis) and/or other mechanisms of cell death (Eastman,
1987,1990). It has been suggested that defects in the apoptotic
pathway can result in chemotherapy resistance (Dive and
Hickman, 1991). Many genes that either positively or negatively
influence apoptosis have been identified among which are the p53
tumour suppressor gene product and members of the BCL-2 gene
family of apoptosis regulators. The BCL-2 protein has been related
to the inhibition of apoptosis (Hockenbery et al, 1990) and to
prolonged cell survival following DNA-damage (Miyashita and
Reed, 1993), whereas the BAX protein accelerates apoptosis and
antagonizes the anti-apoptotic function of BCL-2 (Oltvai et al,
1993). BAX has been shown to homodimerize as well as to
heterodimerize with BCL-2, and the balance between BAX and
BCL-2 is crucial for survival following an apoptotic stimulus
(Oltvai et al, 1993). In addition, recent studies have demonstrated
that BCL-2 and BAX regulate not only apoptosis but also the cell
cycle. Interestingly, the tumour suppressor gene TP53, which is
mutated frequently (up to 50%) in epithelial ovarian tumours
(Shelling et al, 1995) is besides cell cycle arrest, senescence and
DNA repair, also implicated in apoptosis. 
There is clear experimental evidence that TP53 aberrations
play a critical role in the development and progression of ovarian
cancer. With respect to ovarian cancer the prognostic value of
TP53 is still controversial (Ferrandina et al, 1999 and references
therein). Tumour heterogeneity, small numbers of tumours and
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doi: 10.1054/ bjoc.2001.2101, available online at http://www.idealibrary.com on  http://www.bjcancer.comdifferent techniques used for studying TP53 may be responsible
for the reported inconsistencies about the prognostic value of
TP53. Furthermore, miscellaneous chemotherapeutic regimens
and different definitions of response make it difficult to evaluate
the predictive value of response to chemotherapy. Since there still
is a controversy with respect to the value of immunohistochem-
ical or molecular based techniques (Casey et al, 1996; Schuyer
et al, 1998; Skilling et al, 1996), we have chosen to utilize both
approaches to study the clinical relevance of TP53. It is also not
known how and to what extent TP53 mutation affects the function
of the protein. More insight could come from the study of its
‘downstream genes’. To date, genes considered to be target genes
of TP53 include BCL-2, BAX, topoisomerase II, multidrug resis-
tance gene 1, insulin like growth factor binding protein-3,
vascular endothelial growth factor and the cell cycle inhibitor
p21/WAF1/CIP1. 
For the present study, we used molecular analyses and immuno-
histochemistry (IHC) to assess the TP53 status and IHC for p21,
BAX and BCL-2 expression in epithelial ovarian tumours. Our
aim was to analyse whether and which protein levels and/or muta-
tional status are significantly related to patient or tumour charac-
teristics, disease outcome and response to platinum-based
chemotherapy. None of the factors investigated showed a clear
association with response to platinum-based chemotherapy.
However, we found that high BAX expression is a favourable
prognosticator in univariate analysis. Our results suggest that
BAX expression may be a prognostic indicator for patients with
ovarian cancer. 
MATERIALS AND METHODS 
Patients and samples 
In the present study 102 ovarian tumour tissue specimens were
included from patients of whom clinical follow-up data were
available. The tumour tissues were obtained from patients who
underwent primary surgery for ovarian cancer between 1988 and
1993 in hospitals in the southwestern part of the Netherlands. The
median age of the patients at the time of surgery was 56 years
(range 27–86). The disease was staged according to the
International Federation of Gynaecology and Obstetrics (FIGO)
(Kottmeier, 1976). Tissue biopsies were placed on ice immediately
following surgery and stored in liquid nitrogen. Ninety-one
samples were resected from the tumour within the ovary
whereas 11 samples were obtained from the tumour extension
to the omentum. Histological typing and grading were assessed
on paraffin-embedded tissue specimens according to the classifi-
cation of the World Health Organization (WHO). All tissue
samples were reviewed by the same pathologist (S H-L). A
detailed description of patient and tumour characteristics is listed
in Table 1. 
Three patients received radiation and 81 patients were treated
with postoperative chemotherapy (Table 1). Platinum-containing
therapy was given to 75 patients (71× Cyclophosphamide
/cisplatin; 3× Cyclophosphamide/carboplatin and 1× taxol/
cisplatin). The remaining six patients received cyclophosphamide
(2× ) or melphalan (3× ) and in one patient treatment was not speci-
fied. Clinical response was assessed according to the standard
WHO response criteria (WH Organization, 1979). Twenty-one
patients had a CR and in six out of these 21 patients complete
remission was confirmed by second-look laparotomy: in three
patients a pathologic CR and in the other three patients micro-
scopic residual disease was observed. Response was not assess-
able in 40 patients, of which 27 had no macroscopic residual
tumour after surgery and 13 had residual tumour less than 1 cm.
The median follow-up for patients still alive was 78 months (range
2–120 months). 
Immunohistochemistry 
Immunohistochemical staining was performed by a peroxidase
labelled streptavidin-biotin-complex technique on 90 tumour
samples. Five micron thick cryostat sections were fixed in 4%
buffered formalin in case of TP53 and p21 or in acetone in case of
BAX and BCL-2 and preincubated with 5% BSA-PBS for 5 min.
Endogenous biotin was blocked with avidin and biotin (Avidin-
biotin blocking kit, Vector Laboratories, Burlingame, CA, USA)
for 10 min respectively. Sections were subsequently incubated
with the appropriate mouse monoclonal for 1 h, i.e. for TP53
clone DO-1 (1:200, Santa Cruz Biotechnology, Santa Cruz, CA,
USA) and DO-7 (1:100, Dako, Glostrup, Denmark); for p21 clone
2G12 (1:100, Pharmingen, San Diego, USA); for BAX clone
4F11 (1 mg/ml, 1:100; Beckman Coulter BV, Mijdrecht, The
Netherlands); for BCL-2 clone 124 (1:100, Dako, Glostrup,
Denmark). After washing with PBS (2× 5 min), biotinylated
rabbit anti mouse Ig (diluted 1:200, Dako) in PBS containing 2%
normal human serum, was applied for 30 min followed by an
incubation with peroxidase labelled streptavidin-biotin-complex
(Vecta Stain Elite Peroxidase kit, Vector Labs, Burlingame, CA,
USA.) for 30 min. Visualisation of the antibodies was performed
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Table 1 Patient and tumour characteristics 
Patient and tumour characteristics No. of patients 
All 102 
FIGO stage
early (I-IIA) 34 
advanced (IIB-IV) 68 
Histologic type
serous 51 
mucinous 13 
endometrioid 17 
clear cell 6 
mixed 7 
poorly differentiated 8 
Tumour grade
1 16 
2 36 
3 42 
unknown 8 
Residual disease
none 42 
≤ 1 cm 28 
> 1 cm 32 
Ascites
present 55 
absent 46 
unknown 1 
Response to chemotherapy* 
complete 21 
partial 4 
stable disease 1 
progressive disease 11 
not assessable 40 
unknown 4 
* For 81 patients who received postoperative chemotherapy. by incubating the sections with diaminobenzidine tetrahydrochlo-
ride (Fluka Chemie, Buchs, Switzerland) in the presence of 3%
hydrogen peroxide for 10 min. All reactions were performed at
room temperature. Sections were finally counterstained with
Harris haematoxylin, dehydrated and mounted with Pertex.
Sections were evaluated by two observers (S H-L and JHF).
When possible, dependent on the amount of tumour tissue, 300
epithelial tumour cells were counted and results were given as the
percentage positive tumour cells. Positive and negative controls
were included. Expression data were divided into two categories:
low (≤ 10% tumour cells) and high (> 10% tumour cells) TP53
expression (Casey et al, 1996; 79 samples evaluable); no p21 (no
staining in any of the tumour cells) and p21 expression (> 0%
tumour cells; 69 samples evaluable); low (≤ 75% tumour cells)
and high (> 75% tumour cells) BAX expression (52 samples
evaluable), as determined by isotonic regression analysis (Barlow
et al, 1993); low (≤ 40% tumour cells) and high (> 40% tumour
cells) BCL-2 expression (Bonetti et al, 1998; 88 samples evalu-
able). Samples were considered not evaluable if: (a) there was
insufficient tissue; (b) sections did not contain 300 epithelial
tumour cells or; (c) sections did not stain appropriately. 
DNA-isolation, PCR-SSCP and sequencing 
The tumour tissue was pulverized in the frozen state to a fine
powder, homogenized in phosphate buffer according to the
EORTC procedure (EORTC group, 1980) and high molecular
weight chromosomal DNA was isolated from 82 tumour speci-
mens, of which 70 were also used in our immunohistochemical
studies. Exons 5–8 of the TP53 gene were analysed by single-
strand conformation polymorphism (SSCP) and products with
an altered electrophoretic mobility were analysed again and
sequenced as described previously (Berns et al, 1996). 
Statistics 
The strength of the associations between TP53, p21, BAX and
BCL-2 used as continuous variables was tested by Spearman rank
correlation or by Pearson’s χ 2-test for categorical variables. To test
whether staining percentages for TP53 differed in tumour speci-
mens with and without a mutation the Mann-Whitney test was
used. A cut-off point for BAX expression was determined using
isotonic regression analysis (Barlow et al, 1993). The relationship
between patient and tumour characteristics and categorised TP53,
p21, BAX and BCL-2 was tested using Pearson’s χ 2-test. In all
analyses unknown ascites and grade were included as a dummy
variable. Overall and progression-free survival probabilities were
calculated by the actuarial method of Kaplan and Meier (1958) and
the log-rank test was used to test for differences between groups
and Cox proportional hazard model was for univariate and multi-
variate survival analysis. To evaluate whether BAX or TP53
contribute to the prognostic value of the classical prognostic
factors in multivariate analyses for progression-free and overall
survival, patients were stratified by age, FIGO stage, residual
tumour rest and the presence of ascites. The likelihood ratio test
was used to test between models with variables in-and excluded.
The associations of variables with response to chemotherapy was
tested using logistic regression analysis. These analyses were done
with STATA statistical software (release 6.0 College Station, TX:
Stata Corp). Two-sided P-values < 0.05 were judged statistically
significant. 
RESULTS 
Immunostaining 
The expression of TP53, p21, BAX and BCL-2 was studied by
immunohistochemistry in primary ovarian tumours. Using the
criteria described in the Methods section, 79 tumours were evalu-
able for TP53 immunostaining with DO1 antibody. In 31 speci-
mens (39%) no nuclear immunoreactivity was detected. For the
other 48 samples, 13 tumour specimens (16%) showed TP53
staining in less than 10% of tumour cells and staining in over 10%
of tumour cells was observed in 35 (44%) tumours. These latter
specimens were considered positive. Nuclear p21 expression was
evaluated in 69 ovarian tumours. Nineteen specimens (28%)
demonstrated p21 immunoreactivity and were defined as positive.
BAX immunostaining was evaluable in 52 tumours. Cytoplasmic
BAX staining was observed in 45 tumours and according to the
cut-off point of 75% tumour cells 40 tumours (77%) were positive
for BAX. Cytoplasmic BCL-2 immunostaining was evaluable in
88 tumours. Using the cut-off point of 40% positive tumour cells,
29 (33%) tumours were considered positive. No significant rela-
tionships were observed between TP53, p21, BAX or BCL-2
expression. 
TP53 gene alterations and relationship with
immunostaining 
Eighty-two epithelial ovarian tumour specimens were studied for
TP53 mutations by PCR-SSCP analysis (exons 5 through 8) and
sequencing. Among 36 (44%) tumour samples with altered migra-
tion patterns, 32 gene mutations were detected. These included 22
missense point mutations resulting in an amino acid substitution, 7
nonsense mutations (in 6 tumours) and 2 frameshift deletions,
leading to premature termination of the protein and a splice junc-
tion mutation leading to an altered transcription product. A signif-
icant correlation was observed between TP53 mutation and
immunohistochemical status (P < 0.001). As expected especially
missense mutations correlated with positive immunostaining. Of
the 20 tumour specimens with missense mutations that were both
analysed by sequencing and immunohistochemistry, 19 specimens
were found to be immunopositive (>10% positive tumour cells).
Of the seven tumour specimens with non-missense mutations that
were also analysed by immunohistochemistry, only the sample
with a splice site mutation showed nuclear accumulation of the
TP53 protein. Furthermore, 9 out of 36 mutation-negative speci-
mens, which were analysed for TP53 expression, demonstrated
immunopositivity although the level of expression was lower
(median: 37%; range 15–90%) than in immunopositive tumour
specimens with a confirmed TP53 mutation (median: 90%, range
47–100%; P = 0.0001). 
Relationships with patient and tumour characteristics 
A significant correlation was observed between TP53 mutation or
overexpression and advanced FIGO stage (P = 0.008 and 0.02
respectively) and between TP53 expression and the size of residual
tumour after surgery, i.e. in tumours with a residual tumour rest
larger than 1 cm TP53 expression was found more frequently (P =
0.004; Table 2). In addition, TP53 mutation and TP53 expression
occurred more frequently in serous tumours. Moreover, TP53
mutation and TP53 and BCL-2 expression were less frequently
BAX predicts clinical outcome in ovarian cancer 1361
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Table 2 Relationships of TP53 mutation and TP53, p21, BAX and BCL-2 expression with patient and tumour characteristics 
Gene mutation Protein expression 
TP53 TP53 p21 BAX BCL-2 
Factor n Positive (%) P -value n Positive (%) P -value n Positive (%) P -value n Positive (%) P -value n Positive (%) P -value 
All 80 31 (39) 79 35 (44) 69 19 (28) 52 42 (81) 88 29 (33) 
Age 
≤ median 44 16 (36) 42 17 (40) 37 8 (22) 25 18 (72) 46 16 (35) 
> median 36 15 (42) 0.63 37 18 (49) 0.47 32 11 (34) 0.24 27 22 (81) 0.42 42 13 (31) 0.70 
FIGO-stage 
early 27 5 (19) 27 7 (26) 22 4 (18) 16 13 (81) 29 11 (38) 
advanced 53 26 (49) 0.008 52 28 (54) 0.02 47 15 (32) 0.23 36 27 (75) 0.62 59 18 (31) 0.49 
Tumour rest 
≤ 1 cm 53 17 (32) 54 18 (33) 46 9 (20) 34 28 (82) 59 20 (34) 
> 1 cm 27 14 (52) 0.09 25 17 (68) 0.004 23 10 (43) 0.04 18 12 (67) 0.20 29 9 (31) 0.79 
Ascites 
absent 37 13 (35) 36 13 (36) 31 7 (23) 24 19 (79) 37 10 (27) 
present 42 17 (40) 0.63 42 22 (52) 0.15 37 11 (30) 0.51 28 21 (75) 0.72 50 19 (38) 0.28 
Histology 
serous 38 18 (47) 39 21 (54) 35 10 (29) 27 19 (70) 45 18 (40) 
non-serous 42 13 (31) 0.13 40 14 (35) 0.09 34 9 (26) 0.85 25 21 (84) 0.24 43 11 (26) 0.15 
Grade 
1 11 2 (18) 10 3 (30) 7 2 (29) 9 6 (67) 12 2 (17) 
2 30 12 (40) 28 8 (29) 26 7 (27) 14 13 (93) 31 13 (42) 
3 33 15 (45) 0.27 35 19 (54) 0.09 32 8 (25) 0.98 27 19 (70) 0.21 38 12 (32) 0.28 observed in more differentiated tumours, although these differ-
ences were not significant. Staining for p21 was more often
observed in tumours of patients with residual tumour lesions larger
than 1 cm (P = 0.04). No other significant relations were found
between patient and tumour characteristics and p21, BAX or BCL-
2. This evaluation of tumours with multiple molecular markers
sets up a situation in which multiple univariate analyses are
performed. Table 2 looks at 30 different comparisons. When
correcting for multiple comparisons (Bonferroni) a P-value of less
than 0.01 can be considered significant, which implies that only
TP53 mutation with advanced disease and TP53 expression with
suboptimally debulked disease retains significance. 
Progression-free and overall survival 
In Cox univariate regression analysis, older age, advanced FIGO-
stage, larger tumour rest and ascites at presentation were signifi-
cantly associated with a short progression-free and overall survival
(Table 3). Patients with grade 3 tumours had an early progression
compared to patients with grade 1 tumours. No association was
observed between p21 or BCL-2 expression and progression-free
or overall survival in univariate analysis. Although patients with
BCL-2 positive tumours appeared to have a longer progression
free survival (median: 36 months) and overall survival (median: 59
months) compared to patients with BCL-2 negative tumours
(median PFS: 27 and OS: 34 months), the differences were not
statistically significant (Kaplan-Meier curves not shown). TP53
protein expression was found to be associated with a poor overall
survival (Table 3). Patients with TP53 immunopositive tumours
experienced an earlier death (P = 0.03) compared to patients
with TP53 negative tumours. Although there was a trend toward a
poor progression-free survival in patients with TP53 immunoposi-
tive tumours, this difference was not statistically significant.
Patients whose tumours showed TP53 mutations also tended to
have a worse progression-free and overall survival compared to
patients whose tumours exhibited no mutations. However, these
differences were not statistically significant. Patients with both
mutation- and immuno-negative tumours had a better progression-
free (P = 0.07) and overall survival (P = 0.008) compared to
patients with either one or both parameters positive (not shown). 
High BAX expression (> 75%) was associated with a favourable
progression-free (P = 0.05) and overall survival (P = 0.03; Table 3
and Figures 1A and B). We also analysed the BAX data using a
cut-off value of 40% and the Kaplan Meier curve showed a similar
trend (P = 0.05 for overall survival). The median progression-free
and overall survival of patients in the high BAX group was 27 and
54 months respectively compared to 11 and 18 months in the low
BAX group. In an exploratory subgroup analysis in patients with
advanced disease (n = 32 for PFS; n = 35 for OS), BAX expression
was also significantly associated with a longer progression-free
(RHR: 0.40; 95% CI: 0.17–0.95; P = 0.04) and overall survival
(RHR: 0.43; 95% CI: 0.19–0.97; P = 0.04). Since BAX and BCL-2
are antagonists and known to form heterodimers, we studied
whether the combined evaluation of BAX and BCL-2 expression
provided additional information on overall or progression-free
survival. All patients with a low expression of BAX in their
tumours had a similar poor survival, irrespective of BCL-2 status.
Unexpectedly, of the patients with BAX positive tumours, those
simultaneously expressing BCL-2 showed a longer progression-
free and overall survival compared to patients whose tumours did
not express BCL-2 (Figures 1C and D). 
Multivariate analysis for progression-free and overall
survival 
A possible independent prognostic significance of BAX and TP53
expression was examined by Cox multivariate analysis for progres-
sion-free and overall survival. Univariate analysis (Table 3) showed
that age, FIGO stage, residual tumour rest after cytoreductive
surgery, and the presence of ascites are factors that strongly predict
disease outcome and survival. This has also been described by van
der Burg et al (1996) and Neijt et al (1991). In multivariate analyses
patients were therefore stratified by these factors. For the multi-
variate analysis for progression-free survival BAX and grade, both
significantly related with progression-free survival in univariate
analysis, entered the model. Only BAX expression tended to
predict progression (RHR = 0.35; CI = 0.11–1.11; P = 0.075). For
the multivariate analysis for overall survival BAX or TP53 expres-
sion entered the model but neither were found to be independently
associated with survival. 
Response to platinum-based chemotherapy in
advanced disease 
Of the 68 patients with advanced stage (IIB-IV) disease, 58
patients (FIGO stage IIB/IIC: 3 patients and stage III-IV: 55
patients) received platinum containing first-line chemotherapy.
For three patients response was unknown (stage IIC, 1 patient), 21
patients showed no progression, 19 patients achieved a complete
response, four a partial response, one patient had stable disease
and 10 patients experienced progressive disease, thus the overall
percentage that experienced progressive disease was 19% (10 out
of 55 patients). In an exploratory analysis we studied the associa-
tion of the markers investigated with response to platinum-
containing combination therapy in advanced stage disease. There
was no significant association between response to chemotherapy
(complete or partial response versus stable or progressive disease)
and p21, BAX, BCL-2 and TP53 expression or TP53 mutation. 
DISCUSSION 
Besides the classical prognostic factors, it would be beneficial
for patients with ovarian cancer if there were additional tumour-
associated markers that could more reliably predict the rate of
progression and/or the efficacy of response to chemotherapy. In the
present study we determined the relationship between TP53 muta-
tion and expression and the expression of its downstream genes (i.e.
the cell cycle inhibitor p21, the cell death agonist BAX and its
antagonist BCL-2) and evaluated the outcome in relation to patient
and tumour characteristics, survival and response to platinum-
containing chemotherapy in patients with ovarian cancer. 
In the present study only TP53 expression was found to be
significantly (P = 0.03) associated with a poor overall survival, in
univariate analysis. However, as shown in multivariate analysis,
TP53 expression was not independently associated with survival.
Interestingly, patients whose tumours were both mutation-and
immunonegative had a clear survival advantage compared to
patients whose tumours had either a mutation and/or TP53 over-
expression (RHR: 2.85, P = 0.006). The observation that the
combination of both TP53 expression and mutation data results in
a stronger prediction of outcome has recently been reported by
Wen et al (1999) as well. However, more studies are needed to
verify the prognostic value of the combined expression and
BAX predicts clinical outcome in ovarian cancer 1363
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group of advanced ovarian cancer patients no association between
TP53 expression or mutation and response to platinum-based
chemotherapy was found. This is in agreement with data from
previous immunohistochemical-based studies (Hartmann et al,
1994; Herod et al, 1996; Rohlke et al, 1997; van der Zee et al,
1995) but in contrast to other studies using either immunological
(Dong et al, 1997; Ferrandina et al, 1999) or molecular-based tech-
niques (Buttitta et al, 1997; Righetti et al, 1996). 
The presence of a TP53 aberration is not informative for the
biological function of TP53, thus additional information could be
provided by the study of downstream genes and although TP53
regulates the expression of these genes in vitro (el-Deiry et al,
1993, 1994; Miyashita et al, 1994; Miyashita and Reed, 1995), we
could not confirm any correlation between TP53 mutation or
expression and expression of p21, BCL-2 or BAX in ovarian
tumour specimens. This is consistent with findings from several
other studies (Baekelandt et al, 1999a, 1999b; Diebold et al, 1996;
Herod et al, 1996; Marone et al, 1998) although an inverse correla-
tion between TP53 and BCL-2 (Henriksen et al, 1995) and between
TP53 and p21 (Anttila et al, 1999) has also been reported in ovarian
tumour tissues. The lack of a correlation between TP53 and its
downstream genes may reflect the fact that expression of these
genes is also regulated by TP53-independent pathways. 
Expression of p21 was only associated with tumour rest in this
study. This is in agreement with a recent report that also failed to
find an association between p21 expression and prognosis or
response to platinum-based chemotherapy in specimens from
stage III ovarian cancer patients (Baekelandt et al, 1999a). In
contrast to these findings Anttila et al (1999) reported that low p21
expression, using a polyclonal antibody, is a marker of poor
overall survival. 
No statistically significant association between BCL-2 expres-
sion and survival was found. However, patients with increased
BCL-2 expression tended to have a better progression-free and
overall survival compared to patients with low BCL-2 expression
in their tumours. Several studies have correlated BCL-2 with a
survival advantage in ovarian cancer (Baekelandt et al, 1999b;
Diebold et al, 1996; Henriksen et al, 1995; Herod et al, 1996) but
failed to find an association with overall response to chemotherapy
(Baekelandt et al, 1999b; Herod et al, 1996). In contrast, BCL-2
expression has also been reported to be associated with a poor
prognosis and resistance to chemotherapy (Kassim et al, 1999;
Mano et al, 1999). Since BCL-2 is thought to function as an anti-
apoptotic protein, a correlation between BCL-2 expression and a
favourable outcome may seem paradoxical. This inhibition of
tumour cell growth by BCL-2 has also been observed in certain
solid tumour cell lines (Pietenpol et al, 1994) and in breast cancer
as well (Gasparini et al, 1995). Furthermore, it has been suggested
that BCL-2 plays a role in the suppression of angiogenesis
(Koukourakis et al, 1997). Thus BCL-2 may have different func-
tions in normal differentiated and in cancer cells. Moreover, there
is also evidence that BCL-2 functions as a proapoptotic protein in
some circumstances since over-expression of the BCL-2 protein
has been shown to increase the half-life of the BAX protein
(Miyashita et al, 1995). 
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Table 3 Cox univariate analysis of progression-free and overall survival 
Factor* Progression-free survival Overall survival 
P-value RHR (95% CI)† P-value RHR (95% CI)†
Age (continuous) 0.03 1.02 (1.00–1.04) 0.004 1.03 (1.01–1.05) 
> 56 vs ≤ 56 years 0.02 1.94 (1.12–3.35) 0.001 2.68 (1.53–4.69) 
FIGO-stage 
advanced vs early < 0.001 8.80 (3.72–20.82) < 0.001 24.95 (6.05–102.88) 
Tumour rest 
>1 cm vs ≤ 1 cm < 0.001 5.53 (3.08–9.94) < 0.001 6.01 (3.40–10.64) 
FIGO-stage /Tumour rest 
advanced/ ≤ 1 cm vs early < 0.001 6.33 (2.57–15.61) < 0.001 17.77 (4.19–75.37) 
advanced/ > 1 cm vs early 18.17 (7.10–46.48) 42.71 (10.02–182.06) 
Ascites 
present vs absent 0.01 2.11 (1.20–3.72) < 0.001 3.05 (1.68–5.56) 
Histology 
non-serous vs serous 0.21 0.71 (0.41–1.21) 0.24 0.73 (0.43–1.24) 
Grade 
grade 2 vs grade 1 0.03 1.95 (0.66–5.80) 0.18 1.27 (0.50–3.21) 
grade 3 vs grade 1 3.27 (1.14–9.36) 1.96 (0.81–4.75) 
TP53 mutation 
mutation vs no mutation 0.10 1.69 (0.91–3.13) 0.10 1.66 (0.91–3.05) 
TP53 expression 
> 10% vs ≤ 10% 0.18 1.53 (0.82–2.83) 0.03 2.01 (1.08–3.74) 
p21 expression 
> 0% vs 0% 0.32 1.40 (0.73–2.68) 0.49 1.26 (0.65–2.47) 
BCL-2 expression 
> 40% vs ≤ 40% 0.37 0.75 (0.39–1.42) 0.31 0.72 (0.38–1.37) 
BAX expression 
> 75% vs ≤ 75% 0.05 0.44 (0.19–1.01) 0.03 0.42 (0.19–0.93) 
PFS (OS): n = 94 (n = 101) for clinico-pathological variables except for ascites and grade (1 respectively 8 missing values); 
n = 48 (n = 51) for Bax expression; n = 82 (n = 87) for Bcl-2 expression; n = 65 (n = 68) for p21 expression; n = 74 (n = 78)
for TP53 expression; n = 73 (n = 79) for TP53 mutation. † RHR: relative hazard rate with 95% confidence interval (CI).  We have demonstrated the clinical relevance of BAX protein
expression. High expression levels of BAX were found to be
associated with an improved progression-free and overall
survival in univariate analysis. When corrected for classical
factors, BAX expression tended to be an independent factor in
multivariate analysis for relapse-free survival. The clinical rele-
vance of BAX expression has also been demonstrated by Tai et al
(1998). In a smaller group of 45 ovarian cancer patients these
authors showed that high BAX levels were associated with
improved disease-free survival only. BAX expression was found
not to be associated with overall survival, probably reflecting the
short follow-up (median: 21 months) of the patients. In contrast,
another study in 215 ovarian cancer patients described that BAX
expression was correlated with a poor clinical outcome (Marx
et al, 1997). 
Since BCL-2 is a critical factor for susceptibility to an apoptotic
stimulus, the ratio of BCL-2 to BAX may be even of greater
importance (Oltvai and Korsmeyer, 1994). Surprisingly, in this
study we observed that the combination of BAX and BCL-2
expression was a better predictor of outcome than BAX expression
alone in both PFS and overall survival. Patients with both BAX
and BCL-2 positive tumours showed an even better survival
compared to patients with BAX positive/BCL-2 negative tumours.
A recent study, on 185 stage III ovarian cancer patients by
Baekelandt et al (2000), also showed that in advanced ovarian
cancer the combined apoptosis related protein BAX and BCL-2
expression data was of independent prognostic significance. One
explanation for this unexpected observation could be that over-
expression of BCL-2 was shown to increase the half-life of BAX,
suggesting a feedback mechanism that may help to maintain the
ration of BCL-2 to BAX protein in physiologically appropriate
ranges (Miyashita et al, 1995). 
It has been suggested that BAX may be involved in the develop-
ment of cisplatin resistance (Perego et al, 1996). A cisplatin-
resistant ovarian cancer cell line was found to have reduced
BAX mRNA levels, which is consistent with the loss of the
ability of TP53 to transactivate BAX as a consequence of TP53
mutation. We, however, have not observed an association between
BAX expression levels and response to platinum-containing
chemotherapy in this small group of patients. Recently, in a larger
group of patients with advanced disease, Baekelandt et al (2000)
also showed no association between BAX and prediction of
response to cisplatin containing chemotherapy. An association
between high BAX levels and improved response to combination
therapy consisting of paclitaxel and cisplatin in a small group of 26
patients was observed by Tai et al (1998). A relation between BAX
and paclitaxel responsiveness has further been suggested by in
vitro studies showing that BAX could preferentially sensitise
ovarian cancer cells to the effects of paclitaxel and vincristine, as
opposed to carboplatin or ionising radiation (Strobel et al, 1996,
1997, 1998). Therefore the relation between BAX expression and
response to paclitaxel needs further investigation. 
In conclusion, TP53 expression but not TP53 mutation was
found to predict overall survival in ovarian cancer patients. The
combined evaluation of TP53 mutation and protein expression
provides additional information, especially in those patients whose
tumours are negative for both expression and mutation.
Furthermore, high BAX expression was found to be associated
BAX predicts clinical outcome in ovarian cancer 1365
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Figure 1 Progression-free and overall survival as a function of BAX immunohistochemical status (A and B) and BAX and BCL-2 immunohistochemical status
combined (C and D). The cut-off point used for BAX expression was 75% and for BCL-2 expression 40% positive tumour cells. Number in parentheses indicate
number of relapses or deaths/total in each group. Numbers do not add up because of missing data for progression-free survival analysis  with a favourable outcome in univariate analysis. The simulta-
neous evaluation of BAX and BCL-2 expression provides addi-
tional prognostic information when compared to BAX alone.
Future studies should therefore focus on the ratio of BCL-2 to
BAX in relation to clinical outcome. To establish the prognostic
significance of these apoptosis related genes in malignant disease
it is adviced to analyse this within large prospective and
randomised studies. 
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